Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.38 |
| ▸ | BRS3 | P32247 | 5/20 | 0.36 |
| ▸ | DHODH | Q02127 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL844426 | 0.94 | AGTR1 (0.38) | AGTR1AGTR2ABCB11EGFRERBB2 | |
| SCHEMBL9291476 | 0.87 | AGTR1 (0.39) | AGTR1AGTR2PDE3A | |
| SCHEMBL8357465 | 0.83 | BRS3 (0.45) | AGTR1AGTR2BRS3 | |
| SCHEMBL6917321 | 0.79 | ABCB11 (0.36) | AGTR1AGTR2ABCB11EGFRERBB2 | |
| SCHEMBL7972081 | 0.77 | AGTR1 (0.35) | AGTR1AGTR2 | |
| SCHEMBL6789844 | 0.77 | PPARG (0.49) | AGTR1AGTR2CYP3A4ADORA3ADRA2B | |
| SCHEMBL4795872 | 0.76 | AGTR1 (0.55) | AGTR1AGTR2ABCB11EGFRERBB2 | |
| SCHEMBL12475515 | 0.76 | BRS3 (0.45) | AGTR1AGTR2BRS3DHODH | |
| SCHEMBL8866651 | 0.76 | DHODH (0.44) | DHODH | |
| SCHEMBL975346 | 0.75 | ABCB11 (0.37) | AGTR1AGTR2ABCB11EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153972-B2 | Benzimidazole derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2006-12-26 | — | — | US | claimed |
| US-20050131039-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2005-06-16 | — | — | US | claimed |
| US-20040219208-A1 | Sustained-release medicines | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-04 | — | — | US | claimed |
| US-20040044223-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2004-03-04 | — | — | US | claimed |
| US-20020151723-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2002-10-17 | — | — | US | claimed |
| JP-8099960-A | — | — | None | — | — | JP | disclosed |
| EP-1984356-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL | MYLAN LAB LTD (IN) | 2012-11-14 | — | — | EP | disclosed |
| US-7943780-B2 | Process for the preparation of candesartan cilexetil | MATRIX LABORATORIES LTD. (IN) | 2011-05-17 | — | — | US | disclosed |
| US-7538133-B2 | Benzimidazole derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20090018344-A1 | PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL | MYLAN LABORATORIES LIMITED (IN) | 2009-01-15 | — | — | US | disclosed |
| EP-1984356-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL | Matrix Laboratories Limited (IN) | 2008-10-29 | — | — | EP | disclosed |
| US-20070259932-A1 | angiotensin II antagonists; Hypotensive agents; cardiovascular disorders; reacting Ethyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-mercaptobenzimidazole-7-carboxylic acid compound with alkylating agent | TAKEDA PHARMACEUTICAL COMPANY, LIMITED | 2007-11-08 | — | — | US | disclosed |
| US-20010047020-A1 | Benzimidazole derivatives, their production and use | TAKEDA PHARAMCEUTICAL COMPANY, LIMITED (JP) | 2001-11-29 | — | — | US | disclosed |
| US-6232334-B1 | HAVE POTENT ANGIOTENSIN II ANTAGONISTIC ACTIVITY AND ANTIHYPERTENSIVE ACTIVITY, FOR TREATING CIRCULATORY SYSTEM DISEASES SUCH AS HYPERTENSIVE DISEASES, HEART DISEASES, STROKES, CEREBRAL APOPLEXY AND NEPHRITIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-15 | — | — | US | disclosed |
| US-6004989-A | ETHYL 2-ETHOXY-1-(2'-1H-TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL) BENZIMIDAZOLE-7-CARBOXYLATE AND SALTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-21 | — | — | US | disclosed |
| JP-H0899960-A | BENZIMIDAZOLE DERIVATIVE | TAKEDA CHEM IND LTD | 1996-04-16 | — | — | JP | disclosed |
| US-5401764-A | Hypotensive agents or cardiovascular disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-03-28 | — | — | US | disclosed |
| US-5196444-A | Angiotensin/II/ antagonists; hypotensive agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-03-23 | — | — | US | disclosed |
| EP-0459136-A1 | Benzimidazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-12-04 | — | — | EP | disclosed |
| JP-H00899960-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018344-A1 | PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL | REN, CA4, SI | AGTR1 8/4885AGTR2 19/4885ABCB11 1393/4885 |
| US-20070259932-A1 | angiotensin II antagonists; Hypotensive agents; cardiovascular disorders; reacting Ethyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-mercaptobenzimidazole-7-carboxylic acid compound with alkylating agent | AGTR1, REN, AGTR2 | AGTR1 1/4885AGTR2 3/4885ABCB11 546/4885 |
| US-20050131039-A1 | Benzimidazole derivatives, their production and use | MRM1, CARM1, H1-4 | AGTR1 1906/4885AGTR2 2490/4885ABCB11 1224/4885 |
| US-20040219208-A1 | Sustained-release medicines | ACE, AGTR2, AGT | AGTR1 5/4885AGTR2 2/4885ABCB11 290/4885 |
| US-20040044223-A1 | Benzimidazole derivatives, their production and use | HAT1, MRM1, H1-4 | AGTR1 2302/4885AGTR2 2919/4885ABCB11 1312/4885 |
| US-20020151723-A1 | Benzimidazole derivatives, their production and use | HAT1, MRM1, NSD1 | AGTR1 2191/4885AGTR2 2836/4885ABCB11 1237/4885 |
| US-20010047020-A1 | Benzimidazole derivatives, their production and use | REN, AGTR1, H1-3 | AGTR1 2/4885AGTR2 11/4885ABCB11 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.